397 related articles for article (PubMed ID: 26891131)
21. Compromised Telomeric Heterochromatin Promotes ALTernative Lengthening of Telomeres.
Voon HPJ; Collas P; Wong LH
Trends Cancer; 2016 Mar; 2(3):114-116. PubMed ID: 28741530
[TBL] [Abstract][Full Text] [Related]
22. ATRX represses alternative lengthening of telomeres.
Napier CE; Huschtscha LI; Harvey A; Bower K; Noble JR; Hendrickson EA; Reddel RR
Oncotarget; 2015 Jun; 6(18):16543-58. PubMed ID: 26001292
[TBL] [Abstract][Full Text] [Related]
23. Integrated mutational landscape analysis of uterine leiomyosarcomas.
Choi J; Manzano A; Dong W; Bellone S; Bonazzoli E; Zammataro L; Yao X; Deshpande A; Zaidi S; Guglielmi A; Gnutti B; Nagarkatti N; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Jeong K; Zhao S; Buza N; Hui P; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Ardighieri L; Bilguvar K; Quick CM; Silasi DA; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Imielinski M; Schwartz PE; Alexandrov LB; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876771
[TBL] [Abstract][Full Text] [Related]
24. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
Fishbein L; Khare S; Wubbenhorst B; DeSloover D; D'Andrea K; Merrill S; Cho NW; Greenberg RA; Else T; Montone K; LiVolsi V; Fraker D; Daber R; Cohen DL; Nathanson KL
Nat Commun; 2015 Jan; 6():6140. PubMed ID: 25608029
[TBL] [Abstract][Full Text] [Related]
25. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.
Bertsch E; Qiang W; Zhang Q; Espona-Fiedler M; Druschitz S; Liu Y; Mittal K; Kong B; Kurita T; Wei JJ
Mod Pathol; 2014 Aug; 27(8):1144-53. PubMed ID: 24390224
[TBL] [Abstract][Full Text] [Related]
26. Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.
Kim HS; Lee HS; Nam KH; Choi J; Kim WH
Anticancer Res; 2015 Jun; 35(6):3501-10. PubMed ID: 26026117
[TBL] [Abstract][Full Text] [Related]
27. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
28. ATRX driver mutation in a composite malignant pheochromocytoma.
Comino-Méndez I; Tejera ÁM; Currás-Freixes M; Remacha L; Gonzalvo P; Tonda R; Letón R; Blasco MA; Robledo M; Cascón A
Cancer Genet; 2016 Jun; 209(6):272-7. PubMed ID: 27209355
[TBL] [Abstract][Full Text] [Related]
29. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
30. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.
Weisbrod AB; Zhang L; Jain M; Barak S; Quezado MM; Kebebew E
Horm Cancer; 2013 Jun; 4(3):165-75. PubMed ID: 23361940
[TBL] [Abstract][Full Text] [Related]
31. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.
Abedalthagafi M; Phillips JJ; Kim GE; Mueller S; Haas-Kogen DA; Marshall RE; Croul SE; Santi MR; Cheng J; Zhou S; Sullivan LM; Martinez-Lage M; Judkins AR; Perry A
Mod Pathol; 2013 Nov; 26(11):1425-32. PubMed ID: 23765250
[TBL] [Abstract][Full Text] [Related]
32. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
Schwartzentruber J; Korshunov A; Liu XY; Jones DT; Pfaff E; Jacob K; Sturm D; Fontebasso AM; Quang DA; Tönjes M; Hovestadt V; Albrecht S; Kool M; Nantel A; Konermann C; Lindroth A; Jäger N; Rausch T; Ryzhova M; Korbel JO; Hielscher T; Hauser P; Garami M; Klekner A; Bognar L; Ebinger M; Schuhmann MU; Scheurlen W; Pekrun A; Frühwald MC; Roggendorf W; Kramm C; Dürken M; Atkinson J; Lepage P; Montpetit A; Zakrzewska M; Zakrzewski K; Liberski PP; Dong Z; Siegel P; Kulozik AE; Zapatka M; Guha A; Malkin D; Felsberg J; Reifenberger G; von Deimling A; Ichimura K; Collins VP; Witt H; Milde T; Witt O; Zhang C; Castelo-Branco P; Lichter P; Faury D; Tabori U; Plass C; Majewski J; Pfister SM; Jabado N
Nature; 2012 Jan; 482(7384):226-31. PubMed ID: 22286061
[TBL] [Abstract][Full Text] [Related]
33. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.
Yoshida M; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Hiraoka N; Sekine S
Br J Cancer; 2015 Oct; 113(8):1244-8. PubMed ID: 26355235
[TBL] [Abstract][Full Text] [Related]
34. Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.
Kämpjärvi K; Mäkinen N; Kilpivaara O; Arola J; Heinonen HR; Böhm J; Abdel-Wahab O; Lehtonen HJ; Pelttari LM; Mehine M; Schrewe H; Nevanlinna H; Levine RL; Hokland P; Böhling T; Mecklin JP; Bützow R; Aaltonen LA; Vahteristo P
Br J Cancer; 2012 Nov; 107(10):1761-5. PubMed ID: 23132392
[TBL] [Abstract][Full Text] [Related]
35. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
[TBL] [Abstract][Full Text] [Related]
36. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
Tsuyoshi H; Yoshida Y
Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
[TBL] [Abstract][Full Text] [Related]
37. TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT.
de Nonneville A; Salas S; Bertucci F; Sobinoff AP; Adélaïde J; Guille A; Finetti P; Noble JR; Churikov D; Chaffanet M; Lavit E; Pickett HA; Bouvier C; Birnbaum D; Reddel RR; Géli V
EMBO Mol Med; 2022 Oct; 14(10):e15859. PubMed ID: 35920001
[TBL] [Abstract][Full Text] [Related]
38. Alternative lengthening of telomeres does exist in various canine sarcomas.
Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
[TBL] [Abstract][Full Text] [Related]
39. ATRX and DAXX: Mechanisms and Mutations.
Dyer MA; Qadeer ZA; Valle-Garcia D; Bernstein E
Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 28062559
[TBL] [Abstract][Full Text] [Related]
40. Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors.
Mangerel J; Price A; Castelo-Branco P; Brzezinski J; Buczkowicz P; Rakopoulos P; Merino D; Baskin B; Wasserman J; Mistry M; Barszczyk M; Picard D; Mack S; Remke M; Starkman H; Elizabeth C; Zhang C; Alon N; Lees J; Andrulis IL; Wunder JS; Jabado N; Johnston DL; Rutka JT; Dirks PB; Bouffet E; Taylor MD; Huang A; Malkin D; Hawkins C; Tabori U
Acta Neuropathol; 2014 Dec; 128(6):853-62. PubMed ID: 25315281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
